Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (AMRS) is frequently featured in news coverage for its activities as a vertically integrated synthetic biology company focused on sustainable ingredients produced via precision fermentation. Company announcements highlight developments across its Lab-to-Market™ technology platform, industrial biomanufacturing assets, strategic partnerships, and financial and operational restructuring efforts.
News about Amyris often covers its strategic transformation initiatives, including programs aimed at cost reduction, portfolio simplification, and changes to its capital structure and liquidity. The company has publicly discussed a transformation program supported by external advisors, as well as the establishment of internal governance structures to oversee these efforts. A significant news event was the commencement of voluntary Chapter 11 proceedings by Amyris and certain domestic subsidiaries, described as a step to facilitate an operational and financial restructuring centered on its core sustainable ingredients business.
Investors and observers can also find updates on Amyris’ industrial biotechnology operations, such as its precision fermentation plant in Barra Bonita, Brazil. Recent news includes Amyris taking full ownership of this plant, investing in additional fermentation capacity, and winding down a joint venture while retaining manufacturing assets and royalty interests related to specific fermented ingredients.
Another recurring theme in Amyris news is the formation and evolution of strategic partnerships and licensing agreements. Press releases describe exclusive licenses for cosmetic ingredients, long-term manufacturing agreements, and collaborations for sustainable squalene and fermented sweetener technologies. Earnings updates and revenue guidance communications provide additional context on how these partnerships, ingredient sales, and technology access activities fit into the company’s broader strategic agenda.
This news page aggregates such company-issued releases and related coverage, offering a centralized view of key developments in Amyris’ synthetic biology, fermentation, partnership, and restructuring activities over time.
Amyris, Inc. (Nasdaq: AMRS) has partnered with Rosie Huntington-Whiteley to create a new venture, Clean Beauty Collaborative. This initiative aims to enhance Amyris' presence in the clean beauty sector, building on existing brands like Biossance and Pipette. The collaborative will develop a cosmetics line under the Rose Inc. brand, with products expected to launch in Q3 2021. Caroline Hadfield will serve as CEO, while Huntington-Whiteley will be the Chief Creative Officer. This partnership reflects Amyris' commitment to sustainable beauty innovations.
Amyris, Inc. (Nasdaq: AMRS) will announce its fiscal 2020 Q3 financial results on November 5, 2020. The earnings call is scheduled for 6:00 AM PT and will feature updates from CEO John Melo, CFO Han Kieftenbeld, and COO Eduardo Alvarez. Investors can access the call by phone or via a live webcast on the company's investor page. Amyris focuses on sustainable ingredients for health and beauty markets, utilizing advanced technologies to produce its consumer brands, including Biossance, Pipette, and Purecane.
Amyris, Inc. (AMRS) has signed a Collaboration and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel RNA vaccine platform, focusing on a COVID-19 vaccine. This partnership combines IDRI's RNA technology with Amyris's semi-synthetic squalene, offering potential advantages like scalability and efficacy. Both organizations will co-own the resulting intellectual property, with a Phase 1 clinical trial expected to start mid-2021. The project aims to address COVID-19 and other infectious diseases, with a completion target in early 2022.
Arzeda has announced a joint development agreement with Amyris to advance the development of high-value ingredients through innovative enzyme design. This collaboration, a continuation of their previous successful project funded by DARPA, involves Arzeda creating novel enzymes that Amyris will integrate into its fermentation processes. The project is milestone-based, with potential for early success payments and shared product commercialization revenues. Both companies anticipate developing fermentation strains featuring Arzeda's designed enzymes by 2021.
Amyris, Inc. (Nasdaq: AMRS) announced on October 1, 2020, that it is providing samples of a sustainable alternative to shark-based vaccine adjuvants to pharmaceutical companies. This alternative, derived from sugarcane, aims to replace non-sustainable shark-derived squalene used in vaccines for influenza and COVID-19. The company expects to commercialize this product in Q4 2020. CEO John Melo emphasized the importance of sustainability in their production process, which protects marine resources while contributing to vaccine efficacy.
Amyris announced that its Pipette baby care brand has been selected as a winner in Alibaba's Tmall Global Go Global 11.11 Pitch Fest. This recognition enables Pipette to launch in China on November 11, 2020, coinciding with Singles' Day, the largest online shopping event globally, with projected sales of $45 billion. Alibaba highlighted Pipette's innovative story and safety focus as key factors in its selection. The launch aims to meet the demand for safe, sustainable baby products among Chinese consumers, enhancing Pipette's market presence and growth potential.
Amyris, Inc. (Nasdaq: AMRS) announced on Sept. 15, 2020, that its Reb M natural sweetener has received approval from Health Canada for use in food products. This sweetener, derived from sugarcane, is part of Amyris' portfolio for home and personal care, food and beverage, and clean beauty markets. Reb M can be used in various food items, providing an alternative to sugar and complying with Canadian labeling laws. Following this approval, over 300 manufacturers are exploring Reb M for product development in Canada, the USA, and Latin America.
Amyris, Inc. (Nasdaq: AMRS) announced that CEO John Melo will present a business overview at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on Sept. 14, 2020, at 10:00 a.m. ET. The company will also engage in virtual one-on-one meetings during the event. Amyris is recognized for its innovation in producing sustainable ingredients for the Clean Health and Beauty markets, featuring brands like Biossance, Pipette, and Purecane. A live webcast of the presentation will be available on its investor relations website.
Amyris, Inc. (Nasdaq: AMRS) has responded to a lawsuit filed by LAVVAN, Inc. on September 10, 2020, claiming patent infringement and trade secret misappropriation. Despite this, Amyris maintains that it has adhered to their Research, Collaboration and License Agreement (RCL Agreement) initiated in March 2019, valued at $300 million. The company emphasizes that its 2020 revenue expectations remain unaffected and that it will vigorously defend against LAVVAN's allegations. Amyris continues to focus on developing sustainable ingredients for Clean Health and Beauty markets.
LAVVAN, Inc. filed an $881 million lawsuit against Amyris (Nasdaq: AMRS) for allegedly using LAVVAN's intellectual property and misappropriating trade secrets. The case, filed in the Southern District of New York, stems from a 2019 collaboration agreement that LAVVAN claims Amyris has violated. LAVVAN seeks damages for trade secret misappropriation and patent infringement, as well as a permanent injunction against Amyris's use of its intellectual property.
